WB
e Expression of PAI-1 in BMMSCs was significantly increased following treatment with any concentration of GC, as shown by qRT-PCR and western blotting.WB
b Expression of PAI-1 in VSMCs was increased by GC treatment and by GB-Exo treatment, as shown by qRT-PCR and c western blotting results.e qRT-PCR and f western blotting also demonstrated that overexpressed PAI-1 was detected in GC-treated and GB-Exo groups in VECs. In particular, GB-Exo groups exhibited dramatically upregulated PAI-1 expression in VECs.WB
f qRT-PCR results demonstrated that the expression levels of PAI-1 were reduced by treatment with miR-133b-3p mimics and increased by treatment with an miR-133b-3p inhibitor in VECs, which was also verified by western blotting (g).| Product Name | PAI-1 antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Mouse Monoclonal antibody to PAI-1 [671-3E5-29]This gene encodes a member of the serine proteinase inhibitor (serpin) superfamily. This member is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis. Defects in this gene are the cause of plasminogen activator inhibitor-1 deficiency (PAI-1 deficiency), and high concentrations of the gene product are associated with thrombophilia. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq] |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG1 |
| Clone Number | 671-3E5-29 |
| Host Species | Mouse |
| Tested Applications | ELISAWB |
| Not yet tested in other applications. Optimal dilutions should be determined experimentally by the researcher.: |
|
| Species Reactivity | HumanPigRabbit |
| Concentration | 1mg/ml |
| Purification | Affinity purified |
| Gene Synonyms | PAI1 PAI 1 |
|---|---|
| Target | Recognizes Plasminogen Activator Inhibitor 1 (PAI-1) |
| Light Chain Type | kappa |
WB
e Expression of PAI-1 in BMMSCs was significantly increased following treatment with any concentration of GC, as shown by qRT-PCR and western blotting.
WB
b Expression of PAI-1 in VSMCs was increased by GC treatment and by GB-Exo treatment, as shown by qRT-PCR and c western blotting results.e qRT-PCR and f western blotting also demonstrated that overexpressed PAI-1 was detected in GC-treated and GB-Exo groups in VECs. In particular, GB-Exo groups exhibited dramatically upregulated PAI-1 expression in VECs.
WB
f qRT-PCR results demonstrated that the expression levels of PAI-1 were reduced by treatment with miR-133b-3p mimics and increased by treatment with an miR-133b-3p inhibitor in VECs, which was also verified by western blotting (g).| Application Notes | Not yet tested in other applications. Optimal dilutions should be determined experimentally by the researcher.: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Keep as concentrated solution. Aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | 0.05M Sodium Phosphate; 0.1M NaCl; 1mM EDTA; pH 6.6 |
